AnaptysBio updates presentation; releases Phase 2 UC topline data

AnaptysBio filed an 8-K noting two communications updates.

Rhea-AI Filing Summary

AnaptysBio filed an 8-K noting two communications updates. The company furnished an updated corporate investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD), which is not deemed “filed” under the Exchange Act. It also filed a press release as Exhibit 99.2 under Item 8.01 announcing top-line Phase 2 data in ulcerative colitis for rosnilimab.

The filing lists Exhibits 99.1 (November 2025 presentation), 99.2 (press release dated November 10, 2025), and 104 (cover page XBRL). No financial results or transactional terms are included in this excerpt.

Insights

Biotech Disclosure Analyst

Material disclosure of top-line Phase 2 data via press release; details sit in Exhibit 99.2, not in this summary 8-K.

**AnaptysBio** filed an 8-K on November 10, 2025 noting two items: an updated corporate investor presentation (Item 7.01) and a filed press release (Item 8.01) announcing top-line Phase 2 data in ulcerative colitis for **rosnilimab**. Item 7.01 materials are furnished, not filed, which limits Section 18 liability and incorporation unless specifically referenced. Item 8.01 places the press release in the record as Exhibit 99.2.

The existence of top-line Phase 2 data is a potential inflection point for a clinical-stage asset, but this 8-K does not include efficacy or safety results. Any impact on development plans, study timelines, or partnering would depend on the specifics contained in Exhibit 99.2 and the updated November 2025 presentation.

Key items to review now are: the endpoints, magnitude and consistency of results, safety signals, and any stated next steps or timing in the press release dated November 10, 2025. Also check the corporate deck for changes to program timelines or strategy. Subsequent filings may follow if the data triggers material decisions.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANAB disclose in this 8-K?

AnaptysBio furnished an updated investor presentation (Exhibit 99.1) and filed a press release (Exhibit 99.2) announcing top-line Phase 2 data in ulcerative colitis for rosnilimab.

Is the investor presentation considered "filed" information for ANAB?

No. Information under Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act.

What is included in the ANAB press release mentioned?

Exhibit 99.2 is a press release dated November 10, 2025, regarding top-line Phase 2 data in ulcerative colitis with rosnilimab.

Which exhibits accompany ANAB’s 8-K?

Exhibit 99.1 (Anaptys Corporate Presentation November 2025), Exhibit 99.2 (press release dated November 10, 2025), and Exhibit 104 (cover page XBRL).

Under which items did ANAB present this information?

Item 7.01 (Regulation FD) for the presentation and Item 8.01 (Other Events) for the press release.

Does this 8-K include financial statements for ANAB?

No financial statements are included; the filing lists only exhibits 99.1, 99.2, and 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 09:10 AM Learn about SEC filing dates

0001370053false00013700532025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 10, 2025

(Date of earliest event reported)

ANAPTYSBIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-37985			20-3828755
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10770 Wateridge Circle, Suite 210,

San Diego, CA 92121

(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			ANAB			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.    Regulation FD.

On November 10, 2025, AnaptysBio, Inc. (“AnaptysBio”) updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 8.01.    Other Items

On November 10, 2025, AnaptysBio issued a press release regarding top-line Phase 2 data in ulcerative colitis with rosnilimab. A copy of the press release is filed herewith as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Exhibit Title or Description
99.1			Anaptys Corporate Presentation November 2025.
99.2			AnaptysBio, Inc. Press Release, dated November 10, 2025.
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						AnaptysBio, Inc.
Date: November 10, 2025						By:			/s/Dennis Mulroy
									Name: Dennis Mulroy
									Title: Chief Financial Officer